The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas.
 
Gulam Abbas Manji
Honoraria - Celgene; Exelixis; Roche/Genentech
Consulting or Advisory Role - Exelixis; Roche/Genentech
Research Funding - Merck (Inst); Plexxikon (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech
 
Brian Andrew Van Tine
Consulting or Advisory Role - Caris Life Sciences; CytRx Corporation; EMD Serono; Johnson & Johnson; Lilly/ImClone; Novartis; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Caris Life Sciences; Johnson & Johnson; Lilly; Novartis
Research Funding - Merck; Pfizer
Expert Testimony - Me1 Patient
 
Shing Mirn Lee
No Relationships to Disclose
 
Alexander Raufi
No Relationships to Disclose
 
Parag Patwardhan
No Relationships to Disclose
 
Lauren Esther Blumberg
No Relationships to Disclose
 
Naomi Sender
No Relationships to Disclose
 
Jennifer Wang
No Relationships to Disclose
 
Daniel Otap
Travel, Accommodations, Expenses - Genentech
 
Shahnaz V. Singh-Kandah
Employment - Driver Group
Consulting or Advisory Role - Immunocore
Travel, Accommodations, Expenses - Immunocore
 
Khanh Tu Do
Consulting or Advisory Role - Jackson Laboratory for Genomic Medicine; Seagen
Research Funding - Lilly (Inst)
 
Angela C. Hirbe
No Relationships to Disclose
 
Gideon Bollag
Employment - Plexxikon
Leadership - Plexxikon
Stock and Other Ownership Interests - Many
Patents, Royalties, Other Intellectual Property - Multiple patents (Inst)
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson; Merck; Pfizer
Honoraria - Array BioPharma; Bayer; Daiichi Sankyo; DarwinHealth; Ellipses Pharma; Fortress Biotech; Human Longevity, Inc; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Consulting or Advisory Role - Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; DarwinHealth; Ellipses Pharma; Fortress Biotech; Gencirq; Human Longevity, Inc; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Daiichi Sankyo; Iovance Biotherapeutics; PTC Therapeutics; PureTech